Literature DB >> 18579604

Pathways of cross-species transmission of synthetically reconstructed zoonotic severe acute respiratory syndrome coronavirus.

Timothy Sheahan1, Barry Rockx, Eric Donaldson, Davide Corti, Ralph Baric.   

Abstract

Zoonotic severe acute respiratory syndrome coronavirus (SARS-CoV) likely evolved to infect humans by a series of transmission events between humans and animals in markets in China. Virus sequence data suggest that the palm civet served as an amplification host in which civet and human interaction fostered the evolution of the epidemic SARS Urbani strain. The prototypic civet strain of SARS-CoV, SZ16, was isolated from a palm civet but has not been successfully cultured in vitro. To propagate a chimeric recombinant SARS-CoV bearing an SZ16 spike (S) glycoprotein (icSZ16-S), we constructed cell lines expressing the civet ortholog (DBT-cACE2) of the SARS-CoV receptor (hACE2). Zoonotic SARS-CoV was completely dependent on ACE2 for entry. Urbani grew with similar kinetics in both the DBT-cACE2 and the DBT-hACE2 cells, while icSZ16-S only grew in DBT-cACE2 cells. The SZ16-S mutant viruses adapted to human airway epithelial cells and displayed enhanced affinity for hACE2 but exhibited severe growth defects in the DBT-cACE2 cells, suggesting that the evolutionary pathway that promoted efficient hACE2 interactions simultaneously abolished efficient cACE2 interactions. Structural modeling predicted two distinct biochemical interaction networks by which zoonotic receptor binding domain architecture can productively engage hACE2, but only the Urbani mutational repertoire promoted efficient usage of both hACE2 and cACE2 binding interfaces. Since dual species tropism was preserved in Urbani, it is likely that the virus evolved a high affinity for cACE2/hACE2 receptors through adaptation via repeated passages between human and civet hosts. Furthermore, zoonotic SARS-CoV was variably neutralized by antibodies that were effective against the epidemic strain, highlighting their utility for evaluating passive immunization efficacy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18579604      PMCID: PMC2519660          DOI: 10.1128/JVI.00818-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Characterization of a novel coronavirus associated with severe acute respiratory syndrome.

Authors:  Paul A Rota; M Steven Oberste; Stephan S Monroe; W Allan Nix; Ray Campagnoli; Joseph P Icenogle; Silvia Peñaranda; Bettina Bankamp; Kaija Maher; Min-Hsin Chen; Suxiong Tong; Azaibi Tamin; Luis Lowe; Michael Frace; Joseph L DeRisi; Qi Chen; David Wang; Dean D Erdman; Teresa C T Peret; Cara Burns; Thomas G Ksiazek; Pierre E Rollin; Anthony Sanchez; Stephanie Liffick; Brian Holloway; Josef Limor; Karen McCaustland; Melissa Olsen-Rasmussen; Ron Fouchier; Stephan Günther; Albert D M E Osterhaus; Christian Drosten; Mark A Pallansch; Larry J Anderson; William J Bellini
Journal:  Science       Date:  2003-05-01       Impact factor: 47.728

2.  Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China.

Authors: 
Journal:  Science       Date:  2004-01-29       Impact factor: 47.728

3.  Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus.

Authors:  Boyd Yount; Kristopher M Curtis; Elizabeth A Fritz; Lisa E Hensley; Peter B Jahrling; Erik Prentice; Mark R Denison; Thomas W Geisbert; Ralph S Baric
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

4.  Prevalence of IgG antibody to SARS-associated coronavirus in animal traders--Guangdong Province, China, 2003.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2003-10-17       Impact factor: 17.586

5.  Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.

Authors:  Barry Rockx; Davide Corti; Eric Donaldson; Timothy Sheahan; Konrad Stadler; Antonio Lanzavecchia; Ralph Baric
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

6.  Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China.

Authors:  Y Guan; B J Zheng; Y Q He; X L Liu; Z X Zhuang; C L Cheung; S W Luo; P H Li; L J Zhang; Y J Guan; K M Butt; K L Wong; K W Chan; W Lim; K F Shortridge; K Y Yuen; J S M Peiris; L L M Poon
Journal:  Science       Date:  2003-09-04       Impact factor: 47.728

7.  Detection of group 1 coronaviruses in bats in North America.

Authors:  Samuel R Dominguez; Thomas J O'Shea; Lauren M Oko; Kathryn V Holmes
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

8.  Coronavirus antibodies in African bat species.

Authors:  Marcel A Müller; Janusz T Paweska; Patricia A Leman; Christian Drosten; Klaus Grywna; Alan Kemp; Leo Braack; Karen Sonnenberg; Matthias Niedrig; Robert Swanepoel
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

9.  SARS-related virus predating SARS outbreak, Hong Kong.

Authors:  Bo Jian Zheng; Ka Hing Wong; Jie Zhou; Kin Ling Wong; Betty Wan Y Young; Li Wei Lu; Shui Shan Lee
Journal:  Emerg Infect Dis       Date:  2004-02       Impact factor: 6.883

10.  Pathological changes in masked palm civets experimentally infected by severe acute respiratory syndrome (SARS) coronavirus.

Authors:  Y Xiao; Q Meng; X Yin; Y Guan; Y Liu; C Li; M Wang; G Liu; T Tong; L-F Wang; X Kong; D Wu
Journal:  J Comp Pathol       Date:  2008-03-17       Impact factor: 1.311

View more
  47 in total

1.  Molecular determinants of severe acute respiratory syndrome coronavirus pathogenesis and virulence in young and aged mouse models of human disease.

Authors:  Matthew Frieman; Boyd Yount; Sudhakar Agnihothram; Carly Page; Eric Donaldson; Anjeanette Roberts; Leatrice Vogel; Becky Woodruff; Diana Scorpio; Kanta Subbarao; Ralph S Baric
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

2.  Multiple scales of selection influence the evolutionary emergence of novel pathogens.

Authors:  Miran Park; Claude Loverdo; Sebastian J Schreiber; James O Lloyd-Smith
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-04       Impact factor: 6.237

Review 3.  Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference.

Authors:  John H Beigel; Hannah H Nam; Peter L Adams; Amy Krafft; William L Ince; Samer S El-Kamary; Amy C Sims
Journal:  Antiviral Res       Date:  2019-04-08       Impact factor: 5.970

4.  Evidence for ACE2-utilizing coronaviruses (CoVs) related to severe acute respiratory syndrome CoV in bats.

Authors:  Ann Demogines; Michael Farzan; Sara L Sawyer
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

5.  Genomic characterization of severe acute respiratory syndrome-related coronavirus in European bats and classification of coronaviruses based on partial RNA-dependent RNA polymerase gene sequences.

Authors:  Jan Felix Drexler; Florian Gloza-Rausch; Jörg Glende; Victor Max Corman; Doreen Muth; Matthias Goettsche; Antje Seebens; Matthias Niedrig; Susanne Pfefferle; Stoian Yordanov; Lyubomir Zhelyazkov; Uwe Hermanns; Peter Vallo; Alexander Lukashev; Marcel Alexander Müller; Hongkui Deng; Georg Herrler; Christian Drosten
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

Review 6.  Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission.

Authors:  Rachel L Graham; Ralph S Baric
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus.

Authors:  Barry Rockx; Eric Donaldson; Matthew Frieman; Timothy Sheahan; Davide Corti; Antonio Lanzavecchia; Ralph S Baric
Journal:  J Infect Dis       Date:  2010-03-15       Impact factor: 5.226

8.  SARS-like WIV1-CoV poised for human emergence.

Authors:  Vineet D Menachery; Boyd L Yount; Amy C Sims; Kari Debbink; Sudhakar S Agnihothram; Lisa E Gralinski; Rachel L Graham; Trevor Scobey; Jessica A Plante; Scott R Royal; Jesica Swanstrom; Timothy P Sheahan; Raymond J Pickles; Davide Corti; Scott H Randell; Antonio Lanzavecchia; Wayne A Marasco; Ralph S Baric
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

Review 9.  The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Authors:  Lanying Du; Yuxian He; Yusen Zhou; Shuwen Liu; Bo-Jian Zheng; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2009-02-09       Impact factor: 60.633

Review 10.  Coronaviruses post-SARS: update on replication and pathogenesis.

Authors:  Stanley Perlman; Jason Netland
Journal:  Nat Rev Microbiol       Date:  2009-06       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.